SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Aranidipine

Item No. 40813

CAS Registry No.:	86780-90-7
Formal Name:	1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-yridinedicarboxylic acid, 3-methyl 5-(2-oxopropyl) ester
Synonym:	MPC-1304
MF:	$C_{19}H_{20}N_2O_7$
FW:	388.4
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Aranidipine is supplied as a solid. A stock solution may be made by dissolving the aranidipine in the solvent of choice, which should be purged with an inert gas. Aranidipine is sparingly soluble (1-10 mg/ml) in DMSO.

Description

Aranidipine is an antagonist of voltage-gated calcium channel $Ca_v3.2$.[1] It inhibits inward currents in *Xenopus* oocytes expressing human $Ca_v3.2$ channels when used at a concentration of 10 µM. Aranidipine (10 mg/kg) decreases mean blood pressure and increases heart rate in spontaneously hypertensive rats (SHRs).[2] It increases aortic and coronary blood flow and decreases blood pressure, but not heart rate, in normotensive dogs when administered at a dose of 0.3 mg/kg. Aranidipine (10 µg/kg) decreases blood pressure, as well as increases coronary blood flow velocity and heart contractile force, in dogs.[3] It inhibits diet-induced increases in serum levels of total cholesterol, phospholipids, and triglycerides, as well as reduces aortic plaque area, in rabbits fed a high-cholesterol diet when administered at doses of 3 or 10 mg/kg. Formulations containing aranidipine have been used in the treatment of hypertension.

References

1. Furukawa, T., Nukada, T., Namiki, Y., *et al.* Five different profiles of dihydropyridines in blocking T-type Ca^{2+} channel subtypes ($Ca_v3.1$ (α_{1G}), $Ca_v3.2$ (α_{1H}), and Cav3.3 (α_{1I})) expressed in *Xenopus* oocytes. *Eur. J. Pharmacol.* **613(1-3)**, 100-107 (2009).
2. Kanda, A., Haruno, A., Miyake, H., *et al.* Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. *J. Cardiovasc. Pharmacol.* **20(5)**, 723-730 (1992).
3. Kanda, A., Haruno, A., Miyoshi, K., *et al.* Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: Comparison with other calcium antagonists. *J. Cardiovasc. Pharmacol.* **22(1)**, 167-175 (1993).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM